1. Home
  2. IKT vs NHS Comparison

IKT vs NHS Comparison

Compare IKT & NHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

HOLD

Current Price

$2.07

Market Cap

201.3M

Sector

Health Care

ML Signal

HOLD

Logo Neuberger Berman High Yield Strategies Fund

NHS

Neuberger Berman High Yield Strategies Fund

HOLD

Current Price

$7.71

Market Cap

239.8M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
IKT
NHS
Founded
2008
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
201.3M
239.8M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
IKT
NHS
Price
$2.07
$7.71
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$6.00
N/A
AVG Volume (30 Days)
1.8M
156.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
13.44%
EPS Growth
67.51
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.33
$6.62
52 Week High
$2.58
$7.94

Technical Indicators

Market Signals
Indicator
IKT
NHS
Relative Strength Index (RSI) 67.70 62.18
Support Level $1.45 $7.37
Resistance Level $2.11 $7.72
Average True Range (ATR) 0.14 0.09
MACD 0.05 -0.00
Stochastic Oscillator 75.36 86.67

Price Performance

Historical Comparison
IKT
NHS

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.

About NHS Neuberger Berman High Yield Strategies Fund

Neuberger Berman High Yield Strategies Fund Inc is a diversified, closed-end management investment company. The company invests in high yield debt securities market. The Fund uses leverage to pursue its investment objective. The Fund may invest in a variety of direct debt instruments, including bank loans, notes and other interests in amounts owed to financial institutions by borrowers, such as companies and governments. Corporate loans in which the Fund may invest will consist of direct obligations of borrowers. The Fund may invest in corporate loans at origination as a co-lender or may acquire loans in the secondary market by purchasing participations in, assignments of or novations of corporate loans.

Share on Social Networks: